Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04264078
Recruitment Status : Not yet recruiting
First Posted : February 11, 2020
Last Update Posted : February 11, 2020
Sponsor:
Collaborators:
Gracell Biotechnologies (Shanghai) Co., Ltd
920th Hospital of Joint Logistics Support Force
The Second Affiliated Hospital of Chongqing Medical University
The Affiliated Hospital Of Guizhou Medical University
Central South University
The First Affiliated Hospital of Kunming Medical College
The General Hospital of Western Theater Command
Second Affiliated Hospital of Xi'an Jiaotong University
Nanfang Hospital of Southern Medical University
Fujian Medical University Union Hospital
The First Affiliated Hospital of Anhui Medical University
Tang-Du Hospital
Information provided by (Responsible Party):
Xi Zhang, MD, Xinqiao Hospital of Chongqing

Brief Summary:
The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical experiments is cheerful.however, how to select the functional T cells from the malignant T cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of the host as the material of anti-CD7 universal CAR-T cells could be accessible and affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies.

Condition or disease Intervention/treatment Phase
T-cell Leukemia T-cell Lymphoma Biological: CD7 UCAR-T cells Drug: Fludarabine Drug: Cytoxan Drug: Melphalan Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Anti-CD7 Universal CAR-T Cells for CD7+ T/NK Cell Hematologic Malignancies: a Multi-center, Uncontrolled Trial
Estimated Study Start Date : April 1, 2020
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : April 1, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: anti-CD7 UCAR-T cells
After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD7 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated
Biological: CD7 UCAR-T cells
Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg

Drug: Fludarabine
30mg/m^2 per day for 6 days

Drug: Cytoxan
300mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline

Drug: Melphalan
50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline




Primary Outcome Measures :
  1. the anti-tumor efficiency of anti-CD7 UCAR-T cells [ Time Frame: 4 weeks after infusion ]
    ratio of bone marrow blast cells and/or the measurable lesion size and standralized uptake value


Secondary Outcome Measures :
  1. the long-term efficiency of anti-CD7 UCAR-T cells [ Time Frame: 3 and 6 months after infusion ]
    ratio of bone marrow blast cells and/or the measurable lesion size and standralized uptake value



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LLy), or T-non-Hodgkin lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia/lymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal NK/T cell lymphoma, Mycosis fungoides/ Sezary Syndrome Stage IIB or higher))

    2. CD7-positive tumor (≥20% CD7 positive blasts by flow cytometry or immunohistochemistry (tissue))

    3. Hgb ≥ 7.0 (can be transfused)

    4. Life expectancy greater than 12 weeks

    5. Informed consent explained to, understood by and signed by the patient/guardian. Patient/guardian is given a copy of informed consent.

Exclusion Criteria:

  1. Pregnant or lactating.
  2. Tumor in a location where enlargement could cause airway obstruction (per investigator discretion).
  3. Active infection with HIV or HTLV.
  4. Clinically significant viral infection or uncontrolled viral reactivation of EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human herpesvirus)-6.
  5. Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF (left ventricular shortening fraction)<30% or LVEF(left ventricular ejection fraction)<50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart Association) III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months of treatment).
  6. CNS abnormalities: Presence of CNS(central nervous system)-3 disease defined as detectable cerebrospinal blast cells in a sample of CSF(cerebrospinal fluid) with ≥ 5 WBC( white blood cell)s per mm3 (unless negative by the Steinherz/Bleyer algorithm); Presence of any CNS disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04264078


Contacts
Layout table for location contacts
Contact: Xi Zhang, MD +8613808310064 ext +8613808310064 zhangxxi@sina.com
Contact: Ruihao Huang +8618984398751 ext +8618984398751 1169731117@qq.com

Locations
Layout table for location information
China, Chongqing
Department of Hematology, Xinqiao Hospital
ChongQing, Chongqing, China, 400037
Sponsors and Collaborators
Xinqiao Hospital of Chongqing
Gracell Biotechnologies (Shanghai) Co., Ltd
920th Hospital of Joint Logistics Support Force
The Second Affiliated Hospital of Chongqing Medical University
The Affiliated Hospital Of Guizhou Medical University
Central South University
The First Affiliated Hospital of Kunming Medical College
The General Hospital of Western Theater Command
Second Affiliated Hospital of Xi'an Jiaotong University
Nanfang Hospital of Southern Medical University
Fujian Medical University Union Hospital
The First Affiliated Hospital of Anhui Medical University
Tang-Du Hospital
Investigators
Layout table for investigator information
Principal Investigator: Xi Zhang, MD Xinqiao Hospital of Chongqing
Layout table for additonal information
Responsible Party: Xi Zhang, MD, Chef of Hematology Department, Xinqiao Hospital of Chongqing
ClinicalTrials.gov Identifier: NCT04264078    
Other Study ID Numbers: antiCD7-UCAR-T
First Posted: February 11, 2020    Key Record Dates
Last Update Posted: February 11, 2020
Last Verified: February 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hematologic Neoplasms
Leukemia, T-Cell
Neoplasms
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms by Site
Hematologic Diseases
Leukemia, Lymphoid
Leukemia
Fludarabine
Cyclophosphamide
Melphalan
Antineoplastic Agents
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Myeloablative Agonists